Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes

Laurent, Césari; Delas, Audrey; Gaulard, Philippe; Haı̈oun, Corinne; Moreau, Anne; Xerri, Luc; Traverse-Gléhen, Alexandra; Rousset, Thérèse; Quintin-Roué, Isabelle; Petrella, Tony; Émile, Jean-François; Amara, Nadia; Rochaix, Philippe; Chenard-Neu, Marie-Pierre; Taséi, Anne-Marie; Menet, Emmanuelle; Chomarat, H.; Costes, Valérie; Andrac-Meyer, Lucile; Michiels, Jean‐François; Chassagne‐Clément, Catherine; Leval, Laurence de; Brousset, Pierre; Delsol, Georges; Lamant, Laurence

doi:10.1093/annonc/mdv575

Cited by 195 publications

(229 citation statements)

References 36 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…El LACG ALK-asociado a implantes fue descrito por primera vez en 1997 por Keech y Creech, y hasta el momento existen poco menos de 90 casos publicados 23,24 . Este linfoma corresponde al 0.01-0.5% de los tumores malignos que afectan a la mama 23,25 .…”

Section: Linfoma Anaplásico De Células Grandes Alkasociado a Implanteunclassified

“…Este linfoma corresponde al 0.01-0.5% de los tumores malignos que afectan a la mama 23,25 . En la revisión de 2016 de la clasificación de neoplasias hematopoyéticas de la OMS se incluye el LACG ALK-asociado a implantes mamarios como una entidad diferente por sus características clínico-patológicas específicas 6 .…”

Section: Linfoma Anaplásico De Células Grandes Alkasociado a Implanteunclassified

See 1 more Smart Citation

Linfoma anaplásico de células grandes: estudio clínico-patológico e inmunohistoquímica de 20 casos clasificados de acuerdo a la revisión de la Organización Mundial de la Salud de neoplasias linfoides de 2016

Sevilla-Lizcano¹,

Ortíz-Hidalgo²

2022

GAMO

View full text Add to dashboard Cite

Section: Linfoma Anaplásico De Células Grandes Alkasociado a Implanteunclassified

Linfoma anaplásico de células grandes: estudio clínico-patológico e inmunohistoquímica de 20 casos clasificados de acuerdo a la revisión de la Organización Mundial de la Salud de neoplasias linfoides de 2016

Sevilla-Lizcano¹,

Ortíz-Hidalgo²

2022

GAMO

View full text Add to dashboard Cite

“…Breast implant-associated ALK-ALCL was first described in 1997 by Keech and Creech, and so far there are little less than 90 published cases 23,24 . This lymphoma accounts for 0.01-0.5% of malignant tumors involving the breast 23,25 .…”

Section: Breast Implant-associated Alk-anaplastic Large Cell Lymphomamentioning

confidence: 99%

“…This lymphoma accounts for 0.01-0.5% of malignant tumors involving the breast 23,25 . In the 2016 revision of the WHO classification of hematopoietic neoplasms, breast implant-associated ALK-ALCL is included as a different entity owing to its specific clinicopathological characteristics 6 .…”

Section: Breast Implant-associated Alk-anaplastic Large Cell Lymphomamentioning

confidence: 99%

Anaplastic large cell lymphoma: clinicopathological and immunohistochemical study of 20 cases classified according to the 2016 revision of the World Health Organization classification of lymphoid neoplasms

Sevilla-Lizcano¹,

Ortíz-Hidalgo²

2022

GAMO

View full text Add to dashboard Cite

Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma composed of CD30-positive neoplastic cells. The 2016 revision of the WHO classification of lymphoid neoplasms includes anaplastic lymphoma kinase (ALK) positive, ALK negative and breast implant associated ALCL. ALCL have distinct clinical and prognostic features between positive and negative cases. ALK-1 positive cases mostly occur in the first three decades of life while patients with ALK-1 negative are older. ALCL exhibit a very broad range of cytology appearances that include common pattern, lymphohistiocytic pattern, small-cell pattern, Hodgkin-like pattern and composite pattern. By definition, ALCL show strong CD30 staining on the cell membrane and in the Golgi region and the majority are epithelial membrane antigen positive, express one or more T-cell or Natural Killer antigens and are constantly negative for Epstein-Barr virus. We present the clinicopathologic and immunohistochemical analysis of 20 cases of ALCL studied at a single institution, classified according to the 2016 revision of lymphoid neoplasms. Nine cases were ALK-1 positive, ten ALK-1 negative, and one case as a breast implant associated ALCL ALK-1 negative. (creativecommons.org/licenses/by-nc-nd/4.0/).

show abstract

“…Lahko se pojavi kot njen del ali kot del obprotetične tekočine (6). Ultrazvočno se pogosto kaže s pozno (> 0,5 leta) po operaciji nastalo tekočinsko formacijo, redkeje pa je prisotna solidna tumorska masa (7,8). Histopatološko gre pri tekočinski formaciji (serom) najpogosteje za in situ tumor, ko so anaplastične celice omejene na fibrozno tkivno ovojnico; ima boljšo napoved izida.…”

Section: Razdelitev Anaplastičnih Velikoceličnih Limfomovunclassified

Anaplastični velikocelični limfom, povezan z vsadki dojk

Bajuk

Ahčan

2017

SlovMedJour

View full text Add to dashboard Cite

IzvlečekPo svetu se vedno več žensk odloča za estetsko korekcijo dojk s silikonskimi vsadki in rekonstrukcijo dojk po zdravljenju karcinoma s tkivnim ekspandrom in silikonskim vsadkom. Ocene pravijo, da ima že več kot 10 milijonov žensk po svetu silikonske vsadke dojk. V literaturi je opisanih približno 200 posameznih primerov bolnic z anaplastičnim velikoceličnim limfomom (angl. anaplastic large cell lymphoma, ALCL), ki se povezuje s silikonskimi vsadki. Gre za redko bolezen, ki se po ocenah pojavlja pri 0,1-0,3/100.000 žensk s silikonskimi vsadki letno. Pri kliničnih znakih je potrebno pomisliti tudi na to, sicer zelo redko obliko ALCL. Bolnice so v povprečju stare 50 let. Pri njih se pozno po operaciji lahko pojavi povečanje dojke, bolečina in asimetrija. Pri diagnosticiranju sta pomembni ultrazvočna in citološka preiskava. Ultrazvočno lahko ugotovimo tekočinsko formacijo (serom) ali solidno tumorsko maso. Zdravljenje je individualno. Zaradi narave tumorja je v večini primerov potrebna odstranitev vsadka in popolna odstranitev tkivne ovojnice, katerima sta redko pridruženi kemo-in radioterapija. Petletno preživetje je odvisno od oblike tumorja in dobro korelira s prisotnostjo seroma ali tumorske mase. Pri seromu, ki je pogostejša oblika, je petletno preživetje 100-odstotno, medtem ko je pri solidni tumorski masi petletno preživetje 75-odstotno. Redkost bolezni predstavlja velik diagnostičen izziv, vendar je zgodnje odkrivanje in zdravljenje ključno za ozdravitev bolnic. AbstractAn increasing number of women worldwide decide for esthetic correction of breasts with silicone implants and post-cancer breast reconstruction with tissue expanders and silicone breast implants. It is estimated that more than 10 million women around the globe have them. There are approximately 200 known cases of patients with anaplastic large cell lymphoma (ALCL) linked with silicone breast implants reported in medical literature. ALCL is a rare disease with an annual incidence of 0.1-0.3/100 000 women with breast silicone implants. In the presence of clinical signs, physician should also consider this rare form of ALCL in differential diagnosis. Patients are on average 50 years old. Long after implantation surgery, the patient may experience breast swelling, pain and/or asymmetry. In diagnostics, ultrasound and cytological examination are required. During ultrasound examination fluid formation (seroma) or solid tumor mass can be detected. Treatment is individualized. Due to tumor nature, implant resection and total capsulectomy are usually indicated; also, chemo-and radiotherapy might rarely be required. Five-year survival rate depends on tumor form and correlates well with clinical findings of seroma or solid mass. In the more frequent form, seroma, five-year survival rate is 100 %, while in the case of solid tumor mass five-year survival rate is 75 %. The rarity of this disease makes it difficult to diagnose, but nevertheless, early detection and treatment are important for better recovery.

show abstract

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes

Abstract: In situ i-ALCLs have an indolent clinical course and generally remain free of disease after implant removal. However, infiltrative i-ALCLs could have a more aggressive clinical course that might require additional therapy to implant removal.

Cited by 195 publications

References 36 publications

Linfoma anaplásico de células grandes: estudio clínico-patológico e inmunohistoquímica de 20 casos clasificados de acuerdo a la revisión de la Organización Mundial de la Salud de neoplasias linfoides de 2016

Linfoma anaplásico de células grandes: estudio clínico-patológico e inmunohistoquímica de 20 casos clasificados de acuerdo a la revisión de la Organización Mundial de la Salud de neoplasias linfoides de 2016

Anaplastic large cell lymphoma: clinicopathological and immunohistochemical study of 20 cases classified according to the 2016 revision of the World Health Organization classification of lymphoid neoplasms

Anaplastični velikocelični limfom, povezan z vsadki dojk

Contact Info

Product

Resources

About